Arun A. Azad

246 Clayton Road
Melbourne, VIC 3168, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 222 publications

Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Reply to: Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 31, 2026

Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Journal: Future oncology (London, England)

Published: July 29, 2026

Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer.

Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer.

Journal: Asia-Pacific journal of clinical oncology

Published: June 23, 2026

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Journal: Future oncology (London, England)

Published: June 09, 2026

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Journal: Future oncology (London, England)

Published: June 04, 2026

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

Journal: The New England journal of medicine

Published: June 01, 2026

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

Journal: Future oncology (London, England)

Published: May 11, 2026

Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial.

Radionuclide Combination Strategies in Prostate Cancer: Insights from the AlphaBet Trial.

Journal: European urology focus

Published: April 28, 2026

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.

Journal: BJU international

Published: April 14, 2026

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Journal: Future oncology (London, England)

Published: April 14, 2026

From salvage to spotlight: how 2025 transformed PSMA radioligand therapy.

From salvage to spotlight: how 2025 transformed PSMA radioligand therapy.

Journal: BJU international

Published: April 14, 2026

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 27, 2026

Showing 1-12 of 222

Last Updated: 09/26/2026